vs
天演药业（ADAG）与爱齐科技（ALGN）财务数据对比。点击上方公司名可切换其他公司
天演药业是一家全球化临床阶段生物技术企业，专注于创新型癌症抗体免疫疗法的研发与商业化，依托自主研发的新一代抗体技术平台开发肿瘤靶向治疗药物，核心研发基地位于中国，临床项目覆盖北美、亚洲、欧洲等全球主要市场。
爱齐科技是一家全球知名医疗设备企业，主营设计、生产及销售隐适美透明矫治器、iTero口内扫描仪及配套服务，客户覆盖正畸医师、全科牙医，面向修复、美容牙科领域，业务分为透明矫治器、扫描仪及服务两大板块，可满足青少年等不同群体的正畸需求
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收
ADAG
ALGN
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $995.7M | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $979.3M | ||
| Q4 24 | — | $995.2M | ||
| Q3 24 | — | $977.9M | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | — | $997.4M |
净利润ADAGALGN
| Q4 25 | — | $135.8M | ||
| Q3 25 | — | $56.8M | ||
| Q2 25 | — | $124.6M | ||
| Q1 25 | — | $93.2M | ||
| Q4 24 | — | $103.8M | ||
| Q3 24 | — | $116.0M | ||
| Q2 24 | — | $96.6M | ||
| Q1 24 | — | $105.0M |
毛利率ADAGALGN
| Q4 25 | — | 65.3% | ||
| Q3 25 | — | 64.2% | ||
| Q2 25 | — | 69.9% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 70.0% | ||
| Q3 24 | — | 69.7% | ||
| Q2 24 | — | 70.3% | ||
| Q1 24 | — | 70.0% |
营业利润率ADAGALGN
| Q4 25 | — | 14.8% | ||
| Q3 25 | — | 9.7% | ||
| Q2 25 | — | 16.1% | ||
| Q1 25 | — | 13.4% | ||
| Q4 24 | — | 14.5% | ||
| Q3 24 | — | 16.6% | ||
| Q2 24 | — | 14.3% | ||
| Q1 24 | — | 15.5% |
净利率ADAGALGN
| Q4 25 | — | 13.0% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | — | 12.3% | ||
| Q1 25 | — | 9.5% | ||
| Q4 24 | — | 10.4% | ||
| Q3 24 | — | 11.9% | ||
| Q2 24 | — | 9.4% | ||
| Q1 24 | — | 10.5% |
每股收益（稀释后）ADAGALGN
| Q4 25 | — | $1.88 | ||
| Q3 25 | — | $0.78 | ||
| Q2 25 | — | $1.72 | ||
| Q1 25 | — | $1.27 | ||
| Q4 24 | — | $1.40 | ||
| Q3 24 | — | $1.55 | ||
| Q2 24 | — | $1.28 | ||
| Q1 24 | — | $1.39 |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
